Memorial Sloan-Kettering Cancer Center cell engineering researchers and their clinician colleagues have been in the news recently for a successful experimental cell therapy. Called targeted immunotherapy, a patient's T cells are genetically altered in the lab, then reintroduced with the directive to target and kill cancer cells. The treatment was carried out on a group of adults who all suffered from a rapidly progressing form of leukemia that had not responded to chemotherapy. All five went into remission after the novel cell treatment, and three have stayed that way for a number of months. Results of the ongoing clinical trial appeared in the March 20 online edition of the journal Science Translational Medicine, along with an article in the New York Times.
Tags: 2014, Rockefeller University, 2013, Northeast, Leukemia, immunotherapy, cancer research, New York, Memorial Sloan-Kettering Cancer Center, Cancer Treatment, Immune System, Cell Research, RockU, BioResearch Product Faire Event, NY, New York City, MSKCC